Cagrilintide + Semaglutide is a weight management research compound currently in stock directly from a verified Chinese manufacturer. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
The cagrilintide-semaglutide combination — commonly referenced as CagriSema in clinical research — pairs a long-acting amylin analogue (cagrilintide) with a GLP-1 receptor agonist (semaglutide) in a fixed-ratio co-formulation. The research rationale centers on mechanistic complementarity: amylin receptors and GLP-1 receptors are expressed in distinct but overlapping regions of the hypothalamus and brainstem, with additive or potentially synergistic effects on satiety signaling hypothesized from dual-pathway engagement.
Preclinical studies in rodent models of diet-induced obesity have examined the combination's effects on body weight reduction, food intake, and metabolic parameters. The central hypothesis is that simultaneous amylinergic (hindbrain area postrema, nucleus tractus solitarius) and GLP-1 receptor (hypothalamic arcuate nucleus, ventromedial nucleus) signaling produces greater metabolic response than either pathway alone. This dual-receptor approach represents a broader trend in metabolic peptide research toward multi-target strategies.
PeptidesFromChina.co supplies cagrilintide and semaglutide as individual lyophilized powders, each at 99%+ purity verified by HPLC and Mass Spectrometry, allowing researchers to formulate the combination at custom ratios. Certificates of Analysis accompany every batch. All products are for laboratory research use only and are not for human consumption.
| Combination Components | Cagrilintide (amylin analogue) + Semaglutide (GLP-1 RA) |
|---|---|
| Receptor Targets | AMY1/2/3 (amylin) + GLP-1R (glucagon-like peptide-1 receptor) |
| Clinical Designation | CagriSema |
| Research Areas | Metabolic research, dual-agonism pharmacology, energy homeostasis, body composition |
| Administration Form | Individual lyophilized powders for co-administration |
| Storage | −20°C long-term; 2-8°C aqueous (use promptly) |
| CAS Number | N/A — combination product |
| Molecular Weight | N/A — see individual components |
| Molecular Formula | N/A — combination product |
| Sequence | N/A — combination product |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Cagrilintide 5mg + Semaglutide 5mg | 10 mg | 10 vials | ≥98% | In Stock | $194.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer's internal quality-control records and are not issued as a separate certificate or document.
Research interest in CagriSema centers on whether simultaneous amylin and GLP-1 receptor engagement produces additive or synergistic effects on metabolic endpoints. Studies have examined receptor expression patterns in brainstem and hypothalamic regions, with particular attention to whether the two pathways share downstream signaling nodes or operate independently — a key mechanistic question for combination metabolic research.
Preclinical studies in diet-induced obesity models have examined the combination's effects on fat mass reduction, lean mass preservation, and body weight trajectories. The research question driving much of this work is whether dual-pathway satiety signaling produces greater outcomes than either agent in isolation — and whether the mechanisms are truly complementary or partially redundant.
Studies have investigated glycemic markers, insulin sensitivity, glucagon levels, and gastric emptying rate in rodent models receiving the combination. The distinct receptor mechanisms of each component — amylin's primary role in glucagon suppression versus GLP-1's insulin secretagogue and gastric emptying effects — provides a basis for examining independent versus overlapping metabolic contributions.
We supply cagrilintide and semaglutide as separate lyophilized vials, allowing researchers to formulate at custom ratios. Both components are available individually or together.
Tirzepatide is a GLP-1/GIP dual agonist — a single molecule acting at two incretin receptors. CagriSema combines an amylin analogue with a GLP-1 agonist — two separate molecules acting at distinct receptor systems (amylin receptors vs. incretin receptors). Mechanistically different approaches to multi-receptor metabolic research.
Both cagrilintide and semaglutide are synthesized to 99%+ purity, verified by HPLC and Mass Spectrometry. Certificates of Analysis from the manufacturing facilities are included with each batch.
Both components in lyophilized form should be stored at −20°C, protected from light and moisture. Reconstituted solutions should be kept at 2-8°C and used promptly.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.